Is bone quality associated with collagen age? (Q37426367)

20 August 2017

1 reference

title

Is bone quality associated with collagen age? (English)

1 reference

20 August 2017

D J Leeming

1

1 reference

20 August 2017

K Henriksen

2

1 reference

20 August 2017

I Byrjalsen

3

1 reference

20 August 2017

P Qvist

4

1 reference

20 August 2017

S H Madsen

5

1 reference

20 August 2017

P Garnero

6

1 reference

20 August 2017

M A Karsdal

7

1 reference

20 August 2017

language of work or name

English

0 references

publication date

28 March 2009

1 reference

Osteoporosis International

20 August 2017

1 reference

20 August 2017

20

1 reference

20 August 2017

1461-1470

1 reference

20 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-009-0904-3

20 August 2017

0 references

cites work

Bone quality: what is it and how is it measured?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0904-3

Microdamage in bone: implications for fracture, repair, remodeling, and adaptation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0904-3

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-009-0904-3

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

21 January 2018

1 reference

12 December 2020

Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality

1 reference

12 December 2020

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

1 reference

12 December 2020

The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality.

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

12 December 2020

Do microcracks decrease or increase fatigue resistance in cortical bone?

1 reference

12 December 2020

Effects of osteoporosis medications on bone quality

1 reference

12 December 2020

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

12 December 2020

The role of collagen in bone strength

1 reference

12 December 2020

Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region

1 reference

12 December 2020

1 reference

12 December 2020

Measurement of bone mass and turnover.

1 reference

12 December 2020

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

12 December 2020

Age-dependent fatigue behaviour of human cortical bone.

1 reference

12 December 2020

A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study

1 reference

12 December 2020

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

1 reference

12 December 2020

A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers

1 reference

12 December 2020

Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women.

1 reference

12 December 2020

Microcracks colocalize within highly mineralized regions of cortical bone tissue

1 reference

12 December 2020

Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Biomechanical competence of iliac crest trabecular bone in autosomal dominant osteopetrosis type I

1 reference

12 December 2020

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

1 reference

12 December 2020

Strontium ranelate treatment improves trabecular and cortical intrinsic bone tissue quality, a determinant of bone strength.

1 reference

12 December 2020

Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures

1 reference

12 December 2020

Are nonresorbing osteoclasts sources of bone anabolic activity?

1 reference

12 December 2020

Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease.

1 reference

12 December 2020

Over-suppression of bone turnover: does it exist?

1 reference

12 December 2020

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial

1 reference

12 December 2020

Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise

1 reference

12 December 2020

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density

1 reference

12 December 2020

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk

1 reference

12 December 2020

The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future

1 reference

12 December 2020

Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis

1 reference

12 December 2020

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

1 reference

12 December 2020

Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment

1 reference

12 December 2020

Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

1 reference

12 December 2020

Comparison of Serum and Urine Assays for Biochemical Markers of Bone Resorption in Postmenopausal Women with and without Hormone Replacement Therapy and in Men

1 reference

12 December 2020

Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls

1 reference

12 December 2020

Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis

1 reference

12 December 2020

Osteoclast-derived activity in the coupling of bone formation to resorption.

1 reference

12 December 2020

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

1 reference

12 December 2020

Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential

1 reference

12 December 2020

Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage

1 reference

12 December 2020

How can bone turnover modify bone strength independent of bone mass?

1 reference

12 December 2020

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

1 reference

12 December 2020

Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study

1 reference

12 December 2020

Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae

1 reference

12 December 2020

New mechanisms and targets in the treatment of bone fragility

1 reference

12 December 2020

Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study

1 reference

12 December 2020

Bone strength: the whole is greater than the sum of its parts

1 reference

12 December 2020

Identification of osteopenic women at high risk of fracture: the OFELY study.

1 reference

12 December 2020

Effects of PTH and alendronate on type I collagen isomerization in postmenopausal women with osteoporosis: the PaTH study

1 reference

12 December 2020

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies

1 reference

12 December 2020

Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.

1 reference

12 December 2020

The effect of the microscopic and nanoscale structure on bone fragility

1 reference

12 December 2020

Osteoporosis: diagnosis and management today and tomorrow

1 reference

12 December 2020

Antiremodeling Agents Influence Osteoblast Activity Differently in Modeling and Remodeling Sites of Canine Rib

1 reference

12 December 2020

Who are candidates for prevention and treatment for osteoporosis?

1 reference

12 December 2020

Bone mineral density in sclerosteosis; affected individuals and gene carriers

1 reference

12 December 2020

Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats

1 reference

12 December 2020

Raloxifene enhances vertebral mechanical properties independent of bone density.

1 reference

12 December 2020

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Degradation of bone structural properties by accumulation and coalescence of microcracks.

1 reference

12 December 2020

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

1 reference

12 December 2020

High bone density due to a mutation in LDL-receptor-related protein 5

1 reference

12 December 2020

Osteoclasts prefer aged bone

1 reference

12 December 2020

The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation

1 reference

12 December 2020

A theoretical analysis of the contributions of remodeling space, mineralization, and bone balance to changes in bone mineral density during alendronate treatment.

1 reference

12 December 2020

Aging and matrix microdamage accumulation in human compact bone.

1 reference

12 December 2020

Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone

1 reference

12 December 2020

Targeted and nontargeted remodeling

1 reference

12 December 2020

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

1 reference

12 December 2020

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

1 reference

12 December 2020

Advances in osteoclast biology resulting from the study of osteopetrotic mutations.

1 reference

12 December 2020

Post-translational modifications of proteins: implications for aging, antigen recognition, and autoimmunity

1 reference

12 December 2020

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study

1 reference

12 December 2020

Immunoassay for quantifying type I collagen degradation products in urine evaluated

1 reference

12 December 2020

An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice

1 reference

12 December 2020

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

1 reference

12 December 2020

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

12 December 2020

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Ten years' experience with alendronate for osteoporosis in postmenopausal women

1 reference

12 December 2020

Microcracks in cortical bone: how do they affect bone biology?

1 reference

12 December 2020

1 reference

12 December 2020

Bone quality--the material and structural basis of bone strength and fragility

1 reference

12 December 2020

Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study

1 reference

12 December 2020

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

1 reference

12 December 2020

Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone

1 reference

12 December 2020

Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment

1 reference

12 December 2020

Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone.

1 reference

12 December 2020

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

12 December 2020

10.1007/S00198-009-0904-3

Identifiers

DOI

1 reference

20 August 2017

1 reference